Aurobindo Pharma has received final approval from the US Food & Drug Administration (US FDA) to manufacture and market gabapentin tablets USP 600mg and 800mg.
Gabapentin tablets are the generic equivalent of Pfizer Pharmaceuticals' neurontin tablets, which are indicated for the treatment of partial seizures and other nervous system disorders. The annual sales of gabapentin tablets USP 600mg and 800mg in the US were approximately US$ 220 million for the twelve months ending June 2011 according to IMS and will be launched soon.
Aurobindo now has a total of 139 ANDA approvals (110 Final approvals and 29 Tentative approvals) from US FDA.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients.